Dyadic International has entered into a funded proof of concept research collaboration to explore the potential of its C1 technology to produce two vital therapeutic proteins for human health indications with Mitsubishi Tanabe Pharma Corp.    “We are very pleased to have the opportunity to collaborate with Mitsubishi Tanabe Pharma Corp. to express two of its important therapeutic compounds using our C1 production platform”, said Mark Emalfarb, Dyadic’s chief executive officer. “This rese...